Cellectis (CLLS) EBT Margin Growth (3y) (2018 - 2026)

Cellectis (CLLS) EBT Margin Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,237.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -408.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 363.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cellectis 281.48 Mn 95.81 Mn - 1.24 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.24 Mn
Dec 31, 2025 -81,635.00
Sep 30, 2025 1.34 Mn
Jun 30, 2025 128,946.00
Mar 31, 2025 35,967.00
Dec 31, 2024 -25,887.00
Sep 30, 2024 58,357.00
Jun 30, 2024 42,077.00
Mar 31, 2024 29,650.00
Dec 31, 2023 -3.07 Mn
Sep 30, 2023 -2.46 Mn
Jun 30, 2023 -1.83 Mn
Mar 31, 2023 -1.26 Mn
Dec 31, 2022 80,260.00
Sep 30, 2022 -1.30 Mn
Jun 30, 2022 203,720.00
Mar 31, 2022 208,974.00
Dec 31, 2021 283,929.00
Sep 30, 2021 282,799.00
Jun 30, 2021 -3,164.00